ArrowMark Colorado Holdings LLC boosted its stake in Chimerix Inc. (NASDAQ:CMRX) by 58.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,707,986 shares of the biopharmaceutical company’s stock after purchasing an additional 996,936 shares during the period. ArrowMark Colorado Holdings LLC owned about 5.75% of Chimerix worth $12,538,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the business. Schwab Charles Investment Management Inc. increased its stake in shares of Chimerix by 112.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock valued at $1,055,000 after buying an additional 106,267 shares during the period. Citadel Advisors LLC increased its stake in shares of Chimerix by 131.8% during the third quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock valued at $869,000 after buying an additional 94,108 shares during the period. Nationwide Fund Advisors increased its stake in shares of Chimerix by 70.3% during the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 24,994 shares during the period. Ascend Capital LLC increased its stake in shares of Chimerix by 96.9% during the fourth quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock valued at $3,240,000 after buying an additional 344,311 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of Chimerix during the fourth quarter valued at approximately $280,000. 74.39% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ CMRX traded down $0.36 during mid-day trading on Monday, hitting $4.84. 148,475 shares of the stock traded hands, compared to its average volume of 221,838. Chimerix Inc. has a 52 week low of $4.17 and a 52 week high of $6.57. The firm has a market capitalization of $247.79, a PE ratio of -3.21 and a beta of 1.24.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.07. Chimerix had a negative return on equity of 29.22% and a negative net margin of 1,579.53%. The company had revenue of $1.84 million for the quarter, compared to analyst estimates of $0.83 million. research analysts predict that Chimerix Inc. will post -1.78 EPS for the current year.
CMRX has been the topic of several research analyst reports. Zacks Investment Research cut Chimerix from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. HC Wainwright initiated coverage on Chimerix in a research note on Friday, February 2nd. They set a “buy” rating and a $10.00 target price on the stock. JPMorgan Chase cut Chimerix from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Cowen reissued a “hold” rating and set a $6.00 target price on shares of Chimerix in a research note on Thursday, March 1st. Finally, BidaskClub raised Chimerix from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.06.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.